Posted in

Vector Vaccines: Notable Examples and Applications in Human and Animal Health

by admin••1•Posted inCRISPR, Gene, Vaccine, Vax
Vector Vaccines: Notable Examples and Applications in Human and Animal Health
vectorvaccine.com

Vector Vaccines: Notable Examples and Applications in Human and Animal Health

I. Viral Vector Vaccines

1. Human Medicine

a. Adenoviral Vectors

  • COVID-19 Vaccines:
    • ChAdOx1 (AstraZeneca): A chimpanzee adenovirus vector delivers the SARS-CoV-2 spike protein gene, achieving ~70% efficacy with a single dose .
    • Ad26.COV2.S (Johnson & Johnson): Human adenovirus serotype 26 induces robust immunity after a single injection .
  • Ebola Vaccine:
    • ChAdOx1-GnGc: Protects livestock (sheep, goats, cattle) against Rift Valley fever virus (RVFV) by eliciting neutralizing antibodies comparable to commercial vaccines .

b. Poxvirus Vectors

  • HPV Vaccine: Modified vaccinia Ankara (MVA) expresses HPV L1 protein to prevent cervical cancer .
  • Multivalent Vaccines: Vaccinia and canarypox vectors accommodate >25 kb of foreign DNA, enabling combined vaccines (e.g., rabies + distemper) .

c. Vesicular Stomatitis Virus (VSV) Vectors

  • Ervebo® (rVSV-ZEBOV): A VSV-based vaccine expressing Ebola glycoprotein demonstrates 97.5% efficacy in humans and animals .

d. Newcastle Disease Virus (NDV) Vectors

  • Avian Influenza Vaccine: NDV delivers H5N1 hemagglutinin for poultry immunization, leveraging avian-specific tropism .
2. Veterinary Medicine

a. Poultry Vaccines

  • Vaxxitek® HVT+IBD: A herpesvirus of turkeys (HVT) vector prevents Marek’s disease, infectious bursal disease, and Newcastle disease .
  • Canarypox Virus (CPV): Expresses rabies glycoprotein for oral vaccination in mammals .

b. Livestock Vaccines

  • Adenoviral Vectors: Target bovine viral diarrhea and porcine circovirus via multi-antigen delivery .
  • Pseudorabies Virus (PRV): Controls swine pseudorabies and foot-and-mouth disease through dual-pathogen targeting .

II. Bacterial Vector Vaccines

1. Human Medicine

a. Attenuated Salmonella Vectors

  • Oral Vaccines: Deliver cholera and typhoid antigens to stimulate mucosal immunity .
  • Cancer Immunotherapy: ADXS11-001 (Salmonella secreting HPV16 E7 antigen) shows safety and efficacy in cervical cancer trials .

b. Listeria Vectors

  • Tumor Antigen Delivery: Attenuated Listeria monocytogenes expressing human CD24 enhances Th1/Th2 responses and extends survival in tumor-bearing mice .
2. Veterinary Medicine
  • Salmonella Vectors: Prevent poultry salmonellosis via multi-pathogen antigen co-expression .
  • Lactobacillus Vectors: Oral delivery of porcine epidemic diarrhea virus (PEDV) antigens activates gut immunity in swine .

III. Nucleic Acid Vector Vaccines

1. mRNA Vaccines
  • COVID-19 Vaccines: Non-integrating mRNA platforms (e.g., BioNTech/Moderna) enable rapid pandemic response .
  • Cancer Vaccines: AI-optimized mRNA encodes tumor neoantigens for personalized immunotherapy .
2. DNA Vaccines
  • Rabies Vaccine: Plasmid DNA encoding rabies G protein induces long-term immunity in animals and humans .

IV. Synthetic Biology and Novel Vectors

1. Synthetic Vectors
  • Minimal Genomes: Engineered yeast chromosomes (e.g., for artemisinin production) enhance safety and scalability .
2. Plant Virus/Phage Vectors
  • Tobacco Mosaic Virus (TMV): Low-cost production of influenza antigens, circumventing human pre-existing immunity .

Core Advantages and Challenges

Advantages

  1. High Efficiency: Adenoviruses outperform mRNA vaccines in gene delivery due to natural infectivity .
  2. Multivalent Design: Poxviruses and NDV accommodate 5+ antigens for broad-spectrum protection .
  3. Mucosal Immunity: Salmonella vectors activate gut-associated lymphoid tissue (GALT) via oral administration .

Challenges

  1. Pre-existing Immunity: Common vectors (e.g., Ad5) face neutralization; solutions include rare serotypes (Ad26) or zoonotic vectors (ChAdOx1) .
  2. Manufacturing Complexity: Viral vectors require costly cell-culture systems (e.g., HEK293 cells) .
  3. Safety Concerns: Lentiviral integration risks necessitate long-term carcinogenicity monitoring .

Future Directions

  1. Cross-Species Applications: Adapt veterinary vectors (e.g., NDV) for humans to exploit low pre-existing immunity .
  2. Combo Therapies: Pair vector vaccines with immune checkpoint inhibitors (e.g., PD-1 blockers) to enhance cancer treatment .
  3. AI-Driven Design: Machine learning predicts antigen-epitope compatibility for rapid personalized vaccine development .

Representative Case Studies

Vector Type Example Vaccine Application Key Feature
Adenovirus (ChAdOx1) AstraZeneca COVID-19 Human infectious diseases Single-dose T-cell activation
Poxvirus (MVA) HPV Cervical Cancer Human cancer prevention High-capacity multivalent design
VSV Ervebo® Ebola Zoonotic outbreaks Rapid replication, high efficacy
NDV Avian Influenza Veterinary Low-cost avian-specific delivery
Salmonella ADXS11-001 Cervical Cancer Human oncology Oral delivery, mucosal immunity activation

Data sourced from public references. For collaborations or domain inquiries, contact: chuanchuan810@gmail.com.

了解 RNAmod 的更多信息

订阅后即可通过电子邮件收到最新文章。

One thought on “Vector Vaccines: Notable Examples and Applications in Human and Animal Health”

  1. Vector Vaccines: Definition and Characteristics
    Definition
    A vector vaccine is a biological preparation that utilizes genetically engineered viruses or bacteria as delivery vehicles (vectors) to transport antigen-encoding genes of a target pathogen into host cells. Its core mechanism involves:

    Gene Delivery: Harmless vectors introduce antigen genes into the host cytoplasm or nucleus, leveraging the host’s cellular machinery to express antigenic proteins.
    Immune Activation: Expressed antigens trigger humoral immunity (antibody production) and cellular immunity (T-cell responses), establishing immune memory against the pathogen .
    Technical Classification
    Viral Vector Vaccines
    Adenoviruses (e.g., Ad5, Ad26, ChAdOx1):
    High delivery efficiency, large gene capacity (5–7.5 kb), widely used in COVID-19 vaccines (AstraZeneca, Johnson & Johnson) .
    Poxviruses (e.g., Modified Vaccinia Ankara, MVA):
    Massive genome capacity (>25 kb), non-replicating in humans, ideal for multivalent vaccines .
    Vesicular Stomatitis Virus (VSV):
    Rapid replication, employed in Ebola vaccines (e.g., Ervebo®) .
    Herpesviruses/Lentiviruses:
    Long-term gene expression but carry potential oncogenic risks .
    Bacterial Vector Vaccines
    Attenuated Salmonella/Listeria:
    Oral/mucosal delivery to stimulate mucosal immunity .
    Core Features
    Advantages
    High Efficiency and Targeting:
    Viral vectors naturally infect host cells, outperforming traditional mRNA vaccines in gene delivery .
    Tissue-specific tropism (e.g., adenoviruses target liver cells; VSV targets immune cells) .
    Comprehensive Immune Response:
    Activates CD8+ T cells (cytotoxic), CD4+ T cells (helper), and neutralizing antibodies .
    Mucosal immunity induction via respiratory/intestinal routes blocks pathogen entry .
    Safety and Control:
    Replication-deficient vectors (e.g., E1-deleted adenoviruses) prevent viral replication .
    Non-integrating genomes (e.g., poxviruses, VSV) minimize carcinogenic risks .
    Versatility and Scalability:
    Multiantigen insertion (e.g., MVA expresses 5+ antigens) enables multivalent vaccines .
    Rapid deployment for emerging pathogens (e.g., COVID-19 vaccines in 12 months) .
    Limitations
    Pre-existing Immunity:
    Host antibodies against common vectors (e.g., Ad5) neutralize efficacy. Solutions: rare serotypes (Ad26) or animal-derived vectors (ChAdOx1) .
    Manufacturing Complexity:
    Requires cell-culture systems (e.g., HEK293 cells), increasing costs .
    Potential Risks:
    Lentiviral vectors may integrate into host DNA, requiring long-term safety monitoring .
    Live vectors pose risks for immunocompromised individuals .
    Notable Applications
    COVID-19 Vaccines:
    AstraZeneca (ChAdOx1): Chimpanzee adenovirus delivers SARS-CoV-2 spike protein (70% efficacy) .
    Johnson & Johnson (Ad26.COV2.S): Single-dose Ad26 vector induces robust immunity .
    Ebola Vaccine:
    Ervebo® (rVSV-ZEBOV): VSV vector expressing Ebola glycoprotein (97.5% efficacy) .
    Cancer Prevention:
    HPV Vaccine: Poxvirus vector expresses L1 protein to prevent cervical cancer .
    Future Directions
    Novel Vector Development:
    Synthetic biology-designed minimal genomes enhance safety and delivery .
    Plant viruses/phages circumvent pre-existing immunity and reduce costs .
    Personalized Vaccines:
    AI-driven tumor neoantigen design for precision oncology .
    Combo Therapies:
    Vector vaccines + immune checkpoint inhibitors enhance anticancer efficacy .
    Conclusion
    Vector vaccines bridge genetic engineering and immunology, transforming medicine from “passive defense” to “active design” by:

    Precision Delivery: Exploiting vector biology for cellular targeting.
    Immune Amplification: Multidimensional responses surpassing traditional vaccines.
    Rapid Response: Modular platforms for pandemic preparedness .
    Despite challenges like pre-existing immunity and manufacturing costs, advancements in synthetic biology and AI position vector vaccines as pillars of next-generation immunization, shifting healthcare from “treatment” to “preventive design.”

    Data sourced from public references. For collaborations or domain inquiries,

    回复

发表回复

您的邮箱地址不会被公开。 必填项已用 * 标注